Schwartz G, et al. 2014. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY OUTCOMES trial. Am Heart J;168(5):682–689.
Szarek M, et al. 2019. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol;73(4):387–396.
Steg P, et al. 2019. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation; doi:10.1161/CIRCULATIONAHA.118.038840. [Epub ahead of print].
Schwartz G, et al. 2018. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med;379(22):2097–2107.
Jukema J, et al. 2019. Patients with recent acute coronary syndrome and polyvascular disease derive large absolute benefit from alirocumab: ODYSSEY OUTCOMES trial. J Am Coll Cardiol; doi: 10.1016/j.jacc.2019.03.013. [Epub ahead of print].
Ray KK, et al, Effects of alirocumab on cardiovascular and metabolic outcomes after acute conronary syndrome in patients with and without diabetes: a prespecified anaylsis of the Odyssey Outcomes randomised controlled trial, Lancet Diabetes endocrinol 2019; 7: 618-28.
ACS=acute coronary syndrome; LDL-C low-density lipoprotein cholesterol; MACE=major adverse cardiovascular events; PCSK9=proprotein convertase subtilisin/kexin type 9.
Terms & Policies
Sanofi and Regeneron are collaborating in a global development program and commercialization for Praluent®
See full prescribing information
Sanofi Belgium, MAT-BE-2000786, 1.0, 12/20
©Sanofi 2004-2019 - All rights reserved
Click the "Continue" button below to go to the page you requested or click "Cancel" to remain on this page.